| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Neuroendocrinology Group, Max Planck Institute of Psychiatry, 80804 Munich, Germany
1 Institute of Pathology, Division of Neuropathology, University of Wurzburg, Germany
2 Department of Experimental Medicine, University of L’Aquila, 67100 L’Aquila, Italy CNR, Rome, Italy
3 Division of Neuropathology, Institute of Pathology, Munich Technical University, 81675 Munich, Germany
4 Neurosurgical Department, Hospital San Raffaele 20132 Milan, Italy
5 Endocrine Unit, Department of Internal Medicine and Gastroenterology and Center for Applied Biomedical Research (C.R.B.A.), S. Orsola-Malpighi General Hospital, 40125 Bologna, Italy
(Requests for offprints should be addressed to M Theodoropoulou; Email: marily{at}mpipsykl.mpg.de)
The oncogenic effects of epidermal growth factor (EGF) have long been established. EGF receptor (EGFr) is overexpressed in many types of tumors and constitutes a target for cancer treatment. The pituitary gland is a target of EGF action and it is very likely that EGFr plays a role in pituitary tumor formation and progression. However, there is a controversy in the literature concerning EGFr expression in the different types of pituitary adenomas. In the present study we investigated the expression pattern of the wild type EGFr (EGFrWT) and the constitutively active variant III (EGFrvIII) at the mRNA and protein levels in a large series of pituitary tumors. EGFrWT was found in a high percentage of hormone-secreting tumors, but only in a small fraction of non-functioning pituitary adenomas, while no expression of the EGFrvIII could be detected by nested RT-PCR in any tumor. Among the hormone-secreting adenomas, the highest incidence of EGFr expression was found in Cushing’s pituitary adenomas. Furthermore, immunohistochemistry for the phosphorylated EGFr revealed the presence of activated EGFr in most Cushing’s adenomas, compared with most pituitary adenomas. Taking into account that downregulation of p27/Kip1 plays a significant role in corticotrope tumorigenesis and that EGFr mitogenic signaling results in decreased p27/Kip1, we searched for a correlation between EGFr expression and p27/Kip1 levels in corticotropinomas. Low p27/Kip1 immunoreactivity was observed in corticotropinomas expressing EGFr. On the other hand, somatotropinomas expressing EGFr had high p27/Kip1 immunoreactivity. These data suggest a corticotrope-specific phenomenon and indicate that EGFr may have a role in the unbalanced growth of corticotrope tumoral cells.
This article has been cited by other articles:
|
|
 |
|
  G. Vlotides, E. Siegel, I. Donangelo, S. Gutman, S.-G. Ren, and S. Melmed Rat Prolactinoma Cell Growth Regulation by Epidermal Growth Factor Receptor Ligands Cancer Res., August 1, 2008; 68(15): 6377 - 6386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Vlotides, M. Cruz-Soto, T. Rubinek, T. Eigler, C. J. Auernhammer, and S. Melmed Mechanisms for Growth Factor-Induced Pituitary Tumor Transforming Gene-1 Expression in Pituitary Folliculostellate TtT/GF Cells Mol. Endocrinol., December 1, 2006; 20(12): 3321 - 3335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hubina, A. M Nanzer, M. R Hanson, E. Ciccarelli, M. Losa, D. Gaia, M. Papotti, M. R. Terreni, S. Khalaf, S. Jordan, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur. J. Endocrinol., August 1, 2006; 155(2): 371 - 379. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
